Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been given a consensus rating of “Moderate Buy” by the ten research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $8.1667.

Several equities research analysts have recently weighed in on JSPR shares. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Piper Sandler began coverage on Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price for the company. Finally, Wall Street Zen cut Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $0.72 on Monday. Jasper Therapeutics has a 1-year low of $0.32 and a 1-year high of $3.05. The company has a 50-day moving average of $0.62 and a 200 day moving average of $0.87. The firm has a market cap of $23.83 million, a PE ratio of -0.45 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. Sell-side analysts anticipate that Jasper Therapeutics will post -1.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently added to or reduced their stakes in JSPR. Knott David M Jr raised its stake in Jasper Therapeutics by 5.8% in the fourth quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after buying an additional 10,000 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics in the first quarter worth about $46,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics during the second quarter worth about $78,000. Renaissance Technologies LLC grew its stake in shares of Jasper Therapeutics by 9.0% during the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock worth $416,000 after acquiring an additional 18,683 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at about $35,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.